ASTEX PHARMA (ASTX) Tops Q3 Views; Issues Strong Q4, FY11 Outlook
Tweet
Share
E-mailGet Alerts ASTX Hot Sheet
Join SI Premium – FREE
ASTEX PHARMA (NASDAQ: ASTX) reported Q3 loss of ($0.01), $0.05 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $16.9 million versus the consensus estimate of $16.12 million.
ASTEX PHARMA sees FY2011 EPS of $-0.01, versus the consensus of $-0.03. ASTEX PHARMA sees FY2011 revenue of $20.79 million, versus the consensus of $19.86 million.
ASTEX PHARMA sees FY2011 EPS of $0.05, versus the consensus of $0.17. ASTEX PHARMA sees FY2011 revenue of $66.5 million, versus the consensus of $64.5 million.
ASTEX PHARMA sees FY2011 EPS of $-0.01, versus the consensus of $-0.03. ASTEX PHARMA sees FY2011 revenue of $20.79 million, versus the consensus of $19.86 million.
ASTEX PHARMA sees FY2011 EPS of $0.05, versus the consensus of $0.17. ASTEX PHARMA sees FY2011 revenue of $66.5 million, versus the consensus of $64.5 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
- Nortech Systems, Inc. (NSYS) Tops Q2 EPS by 11c
- Park Dental Partners, Inc. (PARK) Tops Q2 EPS by 28c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
